SalioGen Therapeutics (Series B)

Funding Details
Awarder
Inbox
Date Award
January 05, 2022
Vertical
Genetic Medicine
Funding URL
View Funding Page
Funding Amount:
$115,000,000

Company Info
Founders
Ray Tabibiazar
Company Description
SalioGen Therapeutics has launched Gene Coding, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration Technology (EDITTM) platform. EDIT is based on the novel mammal-derived genomic engineering tool, for use in potentially curative genetic medicines.
Market
Inherited Diseases
Location
Cambridge, MA, USA
Coinvestors
Cystic Fibrosis Foundation, D1 Capital Partners, EPIQ Capital Group, Fidelity Management & Research Company, GordonMD Global Investments, PBM Capital Group, RD Fund, Symbiosis, T. Rowe Price Associates

Links